Work

Monitoring cancer through the blood

Year: 2014

Type: article

Abstract: Tumor biopsies remain the gold standard for the evaluation of genetic changes in tumors either at diagnosis or after treatment with targeted therapies. However, this is not always feasible and can seldom be performed more than once. Noninvasive techniques that measure the allelic burden in blood have the potential to realize genotype‐directed cancer therapy. These technologies can potentially be used for noninvasive tumor genotyping and also provide an opportunity for disease monitoring. Several non‐invasive genotyping technologies are currently under development and being evaluated in patients treated with targeted therapies.

Source: Cancer

DOI: 10.1002/cncr.28967

Authors: Cloud P. Paweletz, Pasi A. Jänne

Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard University

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute